Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Sage Chemical, Inc. et al v. Supernus Pharmaceuticals, Inc. et al
Case Number:
1:22-cv-01302
Court:
Nature of Suit:
Judge:
Firms
- Ballard Spahr
- Barnes & Thornburg
- Heyman Enerio
- Landis Rath
- McCarter & English
- McCollom D'Emilio
- Saul Ewing
- Walden Macht
Companies
Government Agencies
Sectors & Industries:
-
May 10, 2024
Pharmaceutical Cos. Can't Nix Parkinson's Drug Antitrust Suit
A Delaware federal judge has issued a sealed order refusing to dismiss drugmakers Sage Chemical Inc. and TruPharma's antitrust suit accusing rival Supernus Pharmaceuticals and others of suppressing generic versions of the Parkinson's treatment Apokyn.
-
March 21, 2023
FTC Warns Of Harm In Generic Parkinson's Drug Antitrust Suit
The Federal Trade Commission told a Delaware federal court that patients could be significantly harmed by the types of distribution restrictions and other activity that Sage Chemical Inc. accuses its rivals of using to block generic competition for Parkinson's drug Apokyn.
-
December 21, 2022
Drugmaker Dinged For Flouting Del. Court's Counsel Rule
Delaware's chief federal judge has ordered drugmaker Sage Chemical to retain new counsel if it wants to continue pursuing its antitrust suit against rival Supernus and others over Parkinson's drug Apokyn, finding that Sage's representation disregarded a court rule requiring an association with "Delaware counsel."